Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
Interim Data from the Open Label Phase 2 OPTIC Study of Iclusig (ponatinib) for Chronic Phase-CML Presented at the ASCO and EHA Virtual Meetings
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that interim analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Trea
PhaseBio Gets FDA Nod to Begin Study for Coronavirus Treatment
12:00am, Thursday, 28'th May 2020Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential
12:00am, Wednesday, 27'th May 2020
Biopharma companies are among the most resilient among sectors during the coronavirus pandemic, and one large-cap biopharma has a slew of products in its pipeline that have...
Wall Street Breakfast: The Week Ahead
11:16am, Sunday, 24'th May 2020
Welcome to Wall Street Brunch, our preview of stock market events for investors to watch during the upcoming week. You can also catch this article a day early b
Incyte, MorphoSys Application for Lymphoma Drug Validated
12:35pm, Thursday, 21'st May 2020
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
Incyte, MorphoSys Application for Lymphoma Drug Validated
08:35am, Thursday, 21'st May 2020
Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.
5 Top Health Care Stocks to Buy Now on the Goldman Sachs Conviction List
07:24am, Monday, 11'th May 2020
We are only in May, but 2020 is already one of the most incredible years in stock market history.
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2020 Results - Earnings Call Transcript
04:21pm, Tuesday, 05'th May 2020
Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2020 Results - Earnings Call Transcript
Why Incyte's Q1 Loss Isn't As Bad As It Looks
02:36pm, Tuesday, 05'th May 2020
The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.
Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues
11:24am, Tuesday, 05'th May 2020
Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.
Incyte Reports a Q1 Loss Due to MorphoSys Deal
11:02am, Tuesday, 05'th May 2020
The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.
Incyte (INCY) Reports Q1 Loss, Tops Revenue Estimates
09:15am, Tuesday, 05'th May 2020
Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Incyte Revenue Beats Despite Surprise Q1 Loss
07:17am, Tuesday, 05'th May 2020
The Incyte earnings report delivered a negative surprise: a big adjusted Q1 loss. The biotech's revenue beat.
